The impact of renal function on the prognostic value of N-terminal pro–B-type natriuretic peptide in patients with coronary artery disease by Chen, Fei et al.
Address for correspondence: Yong Peng, MD, or Mao Chen, MD, PhD, Department of Cardiology, West China Hospital,  
Sichuan University, 37 Guoxue Street, Chengdu, 610041, PR China, tel: +86 28 85423362, fax: +86 28 85423169,  
e-mail: pengyongcd@126.com (Y. Peng) or hmaochen@vip.sina.com (M. Chen)
Received: 15.10.2017 Accepted: 6.03.2018
*Drs. Fei Chen and Jia-qi Li contributed equally to this work.
CLINICAL CARDIOLOGY
Cardiology Journal 
2019, Vol. 26, No. 6, 696–703
DOI: 10.5603/CJ.a2018.0031 
Copyright © 2019 Via Medica
ISSN 1897–5593
696 www.cardiologyjournal.org
ORIGINAL ARTICLE
The impact of renal function on the prognostic  
value of N-terminal pro–B-type natriuretic peptide  
in patients with coronary artery disease
Fei Chen1*, Jia-qi Li2*, Yuan-Wei-Xiang Ou1, Tian-li Xia1, Fang-yang Huang1,  
Hua Chai1, Bao-tao Huang1, Qiao Li1, Xiao-bo Pu1, Guo-yong Li1,  
Yong Peng1, Mao Chen1, De-jia Huang1
1Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China 
2West China School of Medicine, Sichuan University, Chengdu, China
Abstract
Background: The impact of renal function on the prognostic value of N-terminal pro–B-type natriu-
retic peptide (NT-proBNP) remains unclear in coronary artery disease (CAD). This study sought to 
investigate the value of using NT-proBNP level to predict prognoses of CAD patients with different 
estimated glomerular filtration rates (eGFRs).
Methods: A retrospective analysis was conducted from a single registered database. 2087 consecutive 
patients with CAD confirmed by coronary angiography were enrolled. The primary endpoint was all-
cause mortality.
Results: The mean follow-up time was 26.4 ± 11.9 months and death events occurred in 197 cases. 
The NT-proBNP levels increased with the deterioration of renal function, as well as the optimal cut-
off values based on eGFR stratification to predict endpoint outcome (179.4 pg/mL, 1443.0 pg/mL,  
3478.0 pg/mL, for eGFR ≥ 90, 60–90 and < 60 mL/min/1.73 m2, respectively). Compared with the 
routine cut-off value or overall optimal one, stratified optimal ones had superior predictive ability for 
endpoint in each eGFR group (all with the highest Youden’s J statistics). And the prognostic value be-
came weaker as eGFR level decreased (eGFR ≥ 90 vs. 60–90 vs. < 60 mL/min/1.73 m2, odds ratio [OR] 
7.7; 95% confidence interval [CI] 1.7–33.9 vs. OR 4.8; 95% CI 2.7–8.5 vs. OR 3.0; 95% CI 1.5–6.2).
Conclusions: This study demonstrated that NT-proBNP exhibits different predictive values for progno-
sis for CAD patients with different levels of renal function. Among the assessed values, the NT-proBNP 
cut-off value determined using renal function improve the accuracy of the prognosis prediction of CAD. 
Moreover, lower eGFR is associated with a higher NT-proBNP cut-off value for prognostic prediction. 
(Cardiol J 2019; 26, 6: 696–703)
Key words: coronary artery disease, renal function, N-terminal pro–B-type natriuretic  
peptide, prognosis
Introduction
N-terminal pro–B-type natriuretic peptide 
(NT-proBNP) level [1, 2] and estimated glomeru-
lar filtration rate (eGFR) [3, 4] are important 
predictors of clinical prognosis in patients with 
coronary artery disease (CAD). Prior studies have 
shown that for such patients, NT-proBNP level is 
significantly correlated with eGFR; in particular, 
NT-proBNP level increases as eGFR decreases 
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[5, 6]. Moreover, investigations have also revealed 
that the combined use of NT-proBNP level and 
eGFR can improve the identification of patients at 
high risk of acute myocardial infarction and heart 
failure (HF) [7–9]. Similarly, NT-proBNP levels are 
influenced by age [10]. Research has indicated that 
greater age is associated with a higher NT-proBNP 
cut-off value for diagnosing HF [11]. However, the 
predictive value of NT-proBNP measurements 
remains unclear for patients with different eGFRs.
This study sought to investigate the predic-
tive value of using NT-proBNP level to predict 
prognoses of CAD patients with different eGFRs 
by analysing 2087 consecutive cases of patients 
with CAD.
Methods
Study population
The data source for this investigation was the 
West China Hospital CAD database. This single 
center database prospectively includes all patients 
undergoing coronary angiography with known or 
highly suspected CAD in West China Hospital 
affiliated to Sichuan University. For this analysis, 
consecutive patients with CAD were enrolled from 
July 2008 to January 2012. Patients with CAD were 
eligible for inclusion if they were restricted to 
participants with angiographic evidence of ≥ 50% 
stenosis in ≥ 1 coronary vessels. The exclusion cri-
teria included malignancies, pregnancy, end stage 
renal disease with hemodialysis or renal trans-
plant and severe liver or hematological diseases. 
The above criteria were met by 3375 consecutive 
patients. After further removing those with loss 
of follow-up (n = 312) or incomplete follow-up 
data (n = 61), and patients without presence of 
NT-proBNP data at admission (n = 915), 2087 pa-
tients were included in this data analysis. The study 
protocol was approved by the local institutional 
review boards in accordance with the Declaration 
of Helsinki. All subjects provided written informed 
consent when they were included in the database.
Baseline characteristics
Demographic data, medical history, cardiovas-
cular risk factor, vital signs at admission, medica-
tion at discharge, and final diagnosis were obtained 
from the patient electronic medical records and 
were reviewed by a trained study coordinator. 
Blood samples were collected before angiogra-
phy, and blood biomarkers measured including 
NT-proBNP (measured with an electrochemilu-
minescence immunoassay kit. Roche Diagnostics, 
Grenzach Wyhlen, Germany), liver and kidney 
function (including the admission serum creati-
nine levels), blood glucose, serum lipid, and other 
measurements were analyzed in the Department 
of Laboratory Medicine, West China Hospital, ac-
credited by the College of American Pathologists. 
Hypertension was defined as those with systolic 
blood pressure ≥ 140 mmHg and/or diastolic blood 
pressure ≥ 90 mmHg and/or those receiving anti-
hypertensive medications. Diabetes mellitus was 
diagnosed in patients who had previously under-
gone dietary treatment for diabetes, had received 
additional oral antidiabetic or insulin medication 
or had a current fasting blood glucose level of 
≥ 7.0 mmol/L or random blood glucose level 
≥ 11.1 mmol/L. Patients received care according 
to usual practice; treatment was not affected by 
participation in this study.
Renal function assessment
Serum creatinine was finished before the 
angiography within first 24 h after admission 
and assessed by a nonkinetic alkaline picrate 
(Jaffe) method. The Modification of Diet in Renal 
Disease (MDRD) equation was used to eGFR 
rate in milliliters per minute per 1.73 m2 [12]. 
Patients were divided into three eGFR groups: 
eGFR ≥ 90 mL/min/1.73 m2 (normal renal func-
tion corresponding to strata used to define 
chronic kidney disease stages [13]), 60 ≤ eGFR 
< 90 mL/min/1.73 m2 (mildly impaired renal func-
tion), and eGFR < 60 mL/min/1.73 m2 (moderately 
or severely impaired renal function).
Follow-up and endpoint
The follow-up period ended on January 2013. 
Follow-up information was collected through con-
tact with patients’ physicians, patients or their 
family. All data were corroborated with hospital 
records. The primary endpoint in this study were 
all-cause mortality, as documented in the data-
base. Cardiovascular mortality was not used as 
an endpoint outcome to perform analysis after 
preliminarily calculating statistics power, which 
was insufficient for further analysis due to low 
mortality in the limited follow-up time.
Statistical analysis
Post-hoc analysis was conducted on a ret-
rospective basis. Baseline characteristics were 
compared among patients categorized by admission 
eGFR levels. Continuous variables were expressed 
as mean ± standard deviation (SD) and categorical 
variables were reported as counts (percentages). 
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Analysis of t tests and Pearson c2 tests were used 
to compare the difference for baseline variables 
among eGFR groups, respectively. Kruskal-Wallis 
tests were applied to analyze the difference of 
NT-proBNP levels in patients across renal function 
status, as well as that between patients with and 
without endpoint in the same eGFR group. Trend 
c2 tests were used to evaluate tendency changes 
in all-cause mortality according to eGFR levels 
and NT-proBNP quartiles. For the investigation 
of overall optimal NT-proBNP cut-off value in the 
total population and stratified optimal ones in cor-
responding eGFR groups to predict the endpoint, 
receiving operating characteristic (ROC) analysis 
were conducted. And the following parameters: 
sensitivity, specificity, as well as Youden’s J statis-
tic, an index to measure the performance for these 
cut-off values to discriminate between low and high 
risk individuals in an objective manner [14], were 
calculated for overall and stratified optimal ones, 
and the non-optimal one (300 pg/mL, as proposed in 
the literature [15]) in each eGFR groups. Odds ra-
tios (ORs) and 95% confidence intervals (CIs) were 
calculated based on Binary Logistic Regression 
models, which were used to investigate the risk 
effect of NT-proBNP levels (as categorical vari-
ables, under and above the optimal cut-off values 
or the non-optimal ones) on the outcome events 
in different eGFR groups. Two-sided p values of 
less than 0.05 indicated statistical significance. 
All analyses were performed with SPSS software 
(version 24.0).
Results
A total of 2087 patients with CAD were in-
cluded in this study. Their mean age was 65.0 ± 
± 10.7 years, 21.8% of the patients were female, 
and patients with eGFR ≥ 90 mL/min/1.73 m2 or 
< 60 mL/min/1.73 m2 accounted for 29.6% and 
19.1% of total population, respectively. Patients 
baseline characteristics varied as renal function 
deteriorated; in particular, compared with patients 
in a higher eGFR group, participants in the lower 
eGFR group tended to be older and had a higher 
proportion of female, smoke exposure, hyperten-
sion, diabetes, cardiac dysfunction, and complex 
coronary lesions at admission, and had a lower 
percentage of prescription of antiplatelet drugs 
and statins at discharge (Table 1).
Over a mean follow-up period of 26.4 ± 11.9 
months, 197 endpoint outcomes occurred (all-cause 
mortality rate 9.4%), 107 of that were attributed to 
cardiovascular deaths (cardiac mortality rate 5.1%). 
There was a strong association between renal func-
tion and all-cause or cardiovascular mortality, and 
a similar relationship was also observed between 
NT-proBNP quartiles and all-cause or cardiovascu-
lar mortality (all p values for trend < 0.01) (Fig. 1).
Meanwhile, there was a significant correlation 
between NT-proBNP levels and renal function. The 
NT-proBNP levels increased with the deterioration 
of renal function, median value ranging from 341.0 
pg/mL at eGFR ≥ 90 mL/min/1.73 m2 to 1205.0 
pg/mL at eGFR < 60 mL/min/1.73 m2 in patients 
without all-cause death (p for trend < 0.01), and 
ranging from 900.0 pg/mL to 6086.5 pg/mL in 
patients with all-cause death (p for trend < 0.01), 
meanwhile, the NT-proBNP level of the dead was 
higher than that of survivors in each eGFR group 
(all p < 0.01) (Fig. 2, Table 2).
The overall optimal NT-proBNP cut-off value 
for all patients and the stratified optimal ones for 
patients with corresponding renal function status to 
predict all-cause death determined by ROC analysis 
were as follow: 1440.5 pg/mL for all patients, 179.4 
pg/mL for eGFR ≥ 90 mL/min/1.73 m2, 1443.0 pg/ 
/mL for eGFR ranging 60–90 mL/min/1.73 m2, and 
3478.0 pg/mL for eGFR < 60 mL/min/1.73 m2. 
Compared with non-optimal cut-off value (300 pg/mL) 
and overall optimal one, the stratified optimal one has 
a superior ability to discriminate the risk and predict 
all-cause mortality in each eGFR group (all the three 
with the highest Youden’s J statistics) (Table 3).
After adjustment for potential confounders by 
multivariate logistic regression analysis, strati-
fied optimal NT-proBNP cut-off value, not overall 
optimal one or non-optimal one, which increased 
with the deterioration of renal function status, 
was the first-rank one to predict endpoint in each 
eGFR group, and the prognostic values became 
weaker as eGFR level decreased (eGFR ≥ 90 vs. 
60–90 vs. < 60 mL/min/1.73 m2, OR 7.7; 95% CI 
1.7–33.9 vs. OR 4.8; 95% CI 2.7–8.5 vs. OR 3.0; 
95% CI 1.5–6.2) (Table 4).
Discussion
This study has demonstrated that 1) NT-
-proBNP level is negatively correlated with eGFR 
in CAD patients; 2) the value of NT-proBNP level 
for predicting prognosis varies for CAD patients 
with different eGFRs: A lower eGFR level is indica-
tive of decreased diagnostic value of NT-proBNP 
and a larger optimal NT-proBNP cut-off value for 
predicting prognosis.
The value of NT-proBNP level for predicting 
clinical prognosis in patients with cardiovascular 
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diseases (CVD) has been proven. The use of NT-
-proBNP level in diagnosis has been recommended 
by guidelines for managing HF and acute coronary 
syndrome (ACS) in clinical practice [16, 17]. How-
ever, several studies have found that blood NT- 
-proBNP levels may be significantly affected by re-
nal function [6]. This study found that NT-proBNP 
level is negatively correlated with eGFR in CAD 
patients, and the level is significantly elevated in 
patients with eGFRs of less than 60 mL/min/1.73 m2 
compared with patients with eGFRs of at least 
90 mL/min/1.73 m2. This result is consistent with 
the findings of previous studies. Potential mecha-
nisms to explain the relationship may be complex. 
NT-proBNP is mainly excreted by the kidneys, 
decreases in eGFR lower the body’s ability to clear 
NT-proBNP, resulting in NT-proBNP accumulation 
[18]; moreover, sodium and water retention in pa-
tients with renal dysfunction can cause an increase 
in ventricular wall tension, leading to increased 
secretion of NT-proBNP [19], and the underlying 
pathophysiology of concomitant CVD also make 
contribution to the elevation of NT-proBNP [20]. 
Additional renal-cardiac interactions can further 
complicate the relationship between NT-proBNP 
level and eGFR. Therefore, NT-proBNP levels in 
patients with renal insufficiency may not accurately 
reflect actual cardiac function and prognostic risk; 
Table 1. Baseline characteristics of the study population.
Characteristics eGFR [mL/min/1.73 m2] P
Total ≥ 90 60–90 < 60 
No. of patients 2087 618 1071 398
Age [years] 65.0 ± 10.7 59.1 ± 11.4 66.4 ± 9.6 70.7 ± 7.9 < 0.01
Gender, female 454 (21.8%) 101 (16.3%) 218 (20.4%) 135 (33.9%) < 0.01
Medical history
Current smoking 676 (34.1%) 227 (38.1%) 351 (35.0%) 98 (25.7%) < 0.01
Pre-hypertension 1136 (54.6%) 268 (43.4%) 595 (55.8%) 273 (68.9%) < 0.01
Pre-diabetes mellitus 472 (22.7%) 112 (18.2%) 228 (21.4%) 132 (33.3%) < 0.01
At admission
Systolic blood pressure [mmHg] 130.8 ± 23.6 128.8 ± 24.7 131.4 ± 22.4 132.4 ± 25.1 0.03
Diastolic blood pressure [mmHg] 76.3 ± 13.0 76.7 ± 12.9 76.7 ± 12.6 74.5 ± 14.3 0.01
Heart rate [bpm] 74.8 ± 14.7 74.0 ± 14.0 74.5 ± 14.1 76.9 ± 16.8 0.01
Killip classification ≥ II 268 (12.8%) 69 (11.2%) 123 (11.5%) 76 (19.1%) < 0.01
Left ventricular ejection fraction [%] 59.4 59.7 60.2 56.7 < 0.01
Laboratory values
eGFR [mL/min/1.73 m2] 79.0 ± 24.1 106.3 ± 15.9 75.8 ± 8.3 45.4 ± 12.3 < 0.01
Blood glucose [mmol/L] 7.3 ± 3.5 6.9 ± 2.9 7.1 ± 3.1 8.2 ± 5.0 < 0.01
Diagnosis
ACS 1552 (74.4%) 446 (72.2%) 803 (75.0%) 303 (76.1%) 0.30
STEMI 308 (14.8%) 98 (15.9%) 143 (13.4%) 67 (16.8%) 0.16
Severity of CAD
Left main artery 215 (10.3%) 56 (9.1%) 114 (10.6%) 45 (11.3%) 0.50
Three vessel diseases 569 (27.3%) 143 (23.1%) 285 (26.6%) 141 (35.4%) < 0.01
Discharge medication
Acetylsalicylic acid 1931 (93.5%) 581 (94.8%) 1008 (95.1%) 342 (87.0%) < 0.01
Clopidogrel 1886 (91.3%) 574 (93.6%) 974 (91.9%) 338 (86.0%) < 0.01
Statin 1886 (91.3%) 562 (91.8%) 987 (93.1%) 337 (85.8%) < 0.01
Beta-receptor blockers 1361 (65.9%) 398 (64.9%) 729 (68.8%) 234 (59.5%) < 0.01
ACEI or ARBs 1200 (58.1%) 330 (53.8%) 642 (60.7%) 228 (58.0%) 0.02
Data are expressed as means ± standard deviation or counts and percentages, as appropriate. ACEI — angiotensin converting enzyme inhibitors; 
ACS — acute coronary syndrome; ARB — angiotensin receptor blockers; eGFR — estimated glomerular filtration rate; CAD — coronary artery 
disease; STEMI — ST-segment elevation myocardial infarction
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Figure 1. All-cause and cardiovascular (CV) mortality associated with renal function status and N-terminal pro–B-type 
natriuretic peptide (NT-proBNP) quartiles; eGFR — estimated glomerular filtration rate; CKD stages — chronic kidney 
disease stages: CKD 1 — eGFR ≥ 90 mL/min/1.73 m2; CKD 2 — 90 > eGFR ≥ 60 mL/min/1.73 m2; CKD 3a — 60 > eGFR 
≥ 45 mL/min/1.73 m2; CKD 3b — 45 > eGFR ≥ 30 mL/min/1.73 m2; CKD 4 — 30 > eGFR ≥ 15 mL/min/1.73 m2; CKD 5 
— 15 mL/min/1.73 m2 > eGFR.
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Figure 2. Distribution of N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels according to renal function in 
patients with or without all-cause death. The boxplots show the median, the lower and upper quartiles, and the range 
of data; eGFR — estimated glomerular filtration rate.
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in particular, “over elevation of NT-proBNP” may 
be observed.
Over elevated NT-proBNP levels in patients 
with renal dysfunction may affect the predictive 
value of NT-proBNP for prognosis. This study 
showed that in patients with different renal func-
tion status, the optimal cut-off value of NT-proBNP 
determined via eGFR stratification had superior 
Table 2. N-terminal pro–B-type natriuretic peptide (NT-proBNP) concentrations in patients with or  
without all-cause death across estimated glomerular filtration rate (eGFR) groups.
NT-proBNP [pg/mL] eGFR [mL/min/1.73 m2]
90 ≤ eGFR 60 ≤ eGFR < 90 eGFR ≤ 60
Survivors 341.0 (106.0–1223.0) 371 (123–1330.0) 1205.0 (393.8–3720.0)
Deaths 900.0 (352.0–3753.5) 2875.0 (775.5–5735.8) 6086.5 (1752.5–18722.8)
Data are expressed as median (interquartile).
Table 3. The comparison among non-optimal, overall optimal and stratified optimal and predictive cut-
-off values of plasma N-terminal pro–B-type natriuretic peptide (NT-proBNP) to predict all-cause mortality.
eGFR [mL/min/1.73 m2] NT-proBNP [pg/mL] Sensitivity Specificity Youden’s J statistic
Non-optimal predictive cut-off value of NT-proBNP [pg/mL]
< 60 300.0 0.95 0.21 0.15 
60–90 300.0 0.89 0.45 0.34 
≥ 90 300.0 0.78 0.48 0.27 
Overall optimal predictive cut-off value of NT-proBNP [pg/mL]
< 60 1440.5 0.77 0.55 0.32
60–90 1440.5 0.67 0.76 0.43
≥ 90 1440.5 0.43 0.80 0.23
Stratified optimal predictive cut-off value of NT-proBNP [pg/mL]
< 60 3478.0 0.65 0.75 0.40
60–90 1443.0 0.67 0.76 0.43 
≥ 90 179.4 0.95 0.37 0.31
eGFR — estimated glomerular filtration rate
Table 4. Adjusted odds ratios for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the  
incidence of all-cause mortality.
eGFR
[mL/min/1.73m2]
Strata based on non-optimal  
cut-off value  
of NT-proBNP†
Strata based on overall 
optimal cut-off value  
of NT-proBNP
Strata based on stratified 
optimal cut-off value  
of NT-proBNP†
OR* 95% CI P OR* 95% CI P OR* 95% CI P
< 60 1.9 0.6–5.8 0.28 2.4 1.1–4.9 0.02 3.0 1.5–6.2 < 0.01
60–90 4.0 1.8–8.8 < 0.01 4.8 2.7–8.5 < 0.01 4.8 2.7–8.5 < 0.01
≥ 90 2.5 1.1–6.0 0.04 1.8 0.8–4.1 0.19 7.7 1.7–33.9 < 0.01
†Non-optimal cut-off value of NT-proBNP = 300.0 pg/mL for all patients; overall optimal cut-off value of NT-proBNP = 1440.5 pg/mL for  
overall patients; stratified optimal cut-off value of NT-proBNP = 3478.0 pg/mL for patients with eGFR < 60 mL/min/1.73 m2, 1443.0 pg/mL  
for patients with eGFR 60–90 mL/min/1.73 m2, and 179.4 pg/mL for patients with eGFR ≥ 90 mL/min/1.73 m2.
*Adjusted for age, sex, medical history (pre-hypertension and pre-diabetes mellitus), admission examination (systolic blood pressure, heart 
rate and Killip class), renal function (eGFR), diagnosis of acute coronary syndrome, and discharge medication (statin, angiotensin converting 
enzyme inhibitors or angiotensin receptor blockers and beta-receptor blockers) 
CI — confidence interval; eGFR — estimated glomerular filtration rate; OR — odds ratio
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predictive ability for clinical prognosis than the 
routine cut-off value (NT-proBNP = 300 pg/mL) 
or the overall optimal cut-off value for the en-
tire population of CAD patients, simultaneously, 
a lower eGFR level is indicative of a larger optimal 
NT-proBNP cut-off value for predicting prognosis. 
Similarly, various NT-proBNP cut-off values de-
termined for patients of different ages [7, 21, 22]. 
The underlying mechanism to explain this finding 
is that the increase of NT-proBNP level reflected 
not only impaired renal clearance but also the 
pathophysiological mechanisms of cardio-renal 
diseases [20], and this biomarker is still a useful 
indictor for clinical outcome even in patients with 
moderate or severe renal insufficiency although 
the prognostic value decreases as the deterioration 
of renal function. Accordingly, it is necessary to 
refer to appropriate NT-proBNP cut-off values to 
assess the prognoses of CAD patients with varying 
degrees of renal function. Unfortunately, there is 
a lack of sufficient evidence to determine which 
cut-off values are appropriate for CAD patients 
with renal insufficiency. Thus, NT-proBNP has 
limited utility for predicting prognosis in patients 
with renal insufficiency. Currently, the guidelines 
of management for ACS recommend using NT-
proBNP level to stratify risk for patients with ACS. 
However, the Global Registry of Acute Coronary 
Events (GRACE) score and the Thrombolysis in 
Myocardial Infarction (TIMI) score, which are 
the stratification tools recommended by these 
guidelines, do not include NT-proBNP level as 
a parameter [16]. European Society of Cardiology 
(ESC) guidelines for managing HF issue a state-
ment in 2016 that elevated NT-proBNP level is an 
important indicator of prognosis for patients with 
HF but does not recommend a definite NT-proBNP 
cut-off value for use as a reference. Moreover, 
these guidelines note that NT-proBNP level is 
affected by many factors, including age, renal 
function, atrial fibrillation and other complicating 
diseases. Therefore, patient clinical characteristics 
should be thoroughly considered when NT-proBNP 
levels are used to predict prognoses [17].
The strengths of this study: In clinical prac-
tice, NT-proBNP is an important indicator in the 
diagnosis, treatment and prognostic prediction of 
cardiac function for patients with CVD. The clini-
cal significance of renal function and NT-proBNP 
measurement for prognosis for patients with CVD 
has been investigated by many prior studies; how-
ever, the findings of these studies only reflect the 
predictive value of NT-proBNP level and renal 
function for clinical prognosis [4, 9, 23, 24]. In con-
trast, this study focused on evaluating different 
effects and optimal NT-proBNP cut-off values for 
prognostic prediction in CAD patients with various 
eGFRs. Thus, relative to prior findings, the results 
of this study are more practical with respect to clini-
cal applicability. This study showed that the cut-off 
value of NT-proBNP significantly increases as eGFR 
decreases. The NT-proBNP cut-off value is nearly 
20-fold higher in patients with moderate or severe 
renal failure than in patients with normal renal func-
tion. A similar result was obtained in a previous study 
of patients undergoing non-cardiac surgery [25].
Limitations of the study
This study was a single-centre observational 
study and had a few limitations. First, the registry 
made it difficult to completely avoid selection bias 
and confounding factors. Second, as the inherent 
limitation of the real-world study, the bias from the 
only one-time test of admission serum creatinine 
could not be ruled out completely. Third, objec-
tive echocardiography parameters for systolic and 
diastolic function were not completely collected in 
all participants, and the influence of cardiac func-
tion on NT-proBNP were not well adjusted, only 
when Killip was used as a functional classification 
in statistical analysis. Fourth, the samples in this 
single-center study weresubject to geographical 
restrictions, which affected their representative-
ness and generalization. In summary, caution 
must be taken when analysing the results of this 
study. Moreover, NT-proBNP level is affected by 
many factors, including age, gender and other 
complicating diseases which make it hard to find 
out the optimal cut-off value for prognosis predic-
tion. High-quality research reports are needed to 
provide more clinical evidence on this issue.
Conclusions
This study demonstrated that NT-proBNP ex-
hibits different predictive values for prognosis for 
CAD patients with different levels of renal function. 
Among the assessed values, the NT-proBNP cut-
off value determined using renal function improve 
the accuracy of the prognosis prediction of CAD. 
Moreover, lower eGFR is associated with a higher 
NT-proBNP cut-off value for prognostic prediction. 
These results indicate that in clinical practice, renal 
function must be adequately considered when using 
NT-proBNP level to assess clinical prognosis for 
patients with CAD.
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